Niagen Bioscience (NAGE) EBIAT (2016 - 2025)
Niagen Bioscience (NAGE) has disclosed EBIAT for 15 consecutive years, with $4.1 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT fell 42.44% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.4 million, a 103.46% increase, with the full-year FY2025 number at $17.4 million, up 103.3% from a year prior.
- EBIAT was $4.1 million for Q4 2025 at Niagen Bioscience, down from $4.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $7.2 million in Q4 2024 to a low of -$8.9 million in Q3 2021.
- A 5-year average of -$1.1 million and a median of -$972000.0 in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: plummeted 110.11% in 2021, then surged 24160.0% in 2025.
- Niagen Bioscience's EBIAT stood at -$5.3 million in 2021, then skyrocketed by 73.37% to -$1.4 million in 2022, then surged by 108.04% to $114000.0 in 2023, then soared by 6197.37% to $7.2 million in 2024, then crashed by 42.44% to $4.1 million in 2025.
- Per Business Quant, the three most recent readings for NAGE's EBIAT are $4.1 million (Q4 2025), $4.6 million (Q3 2025), and $3.6 million (Q2 2025).